Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,127,632.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 34,400 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $32.78, for a total value of $1,127,632.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $798,291.34. The trade was a 58.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, January 28th, Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60.
• On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.62, for a total value of $1,298,797.92.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Trading Down 1.4%

Shares of NASDAQ:NAMS opened at $31.44 on Friday. The stock has a market capitalization of $3.56 billion, a PE ratio of -15.34 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The firm has a fifty day moving average price of $35.20 and a 200 day moving average price of $31.25.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NAMS. Simon Quick Advisors LLC bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $202,000. UBS Group AG grew its stake in shares of NewAmsterdam Pharma by 17.0% during the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock worth $31,552,000 after purchasing an additional 130,922 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in NewAmsterdam Pharma by 34.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,477 shares of the company’s stock valued at $929,000 after purchasing an additional 6,735 shares during the last quarter. NBC Securities Inc. acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at about $86,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in NewAmsterdam Pharma by 167.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,804 shares of the company’s stock worth $695,000 after buying an additional 12,400 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

NAMS has been the subject of a number of recent analyst reports. HC Wainwright assumed coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 target price for the company. Citigroup upped their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Stifel Nicolaus upped their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.